AU2005300310A1 - Methods of preparing indazole compounds - Google Patents

Methods of preparing indazole compounds Download PDF

Info

Publication number
AU2005300310A1
AU2005300310A1 AU2005300310A AU2005300310A AU2005300310A1 AU 2005300310 A1 AU2005300310 A1 AU 2005300310A1 AU 2005300310 A AU2005300310 A AU 2005300310A AU 2005300310 A AU2005300310 A AU 2005300310A AU 2005300310 A1 AU2005300310 A1 AU 2005300310A1
Authority
AU
Australia
Prior art keywords
formula
compound
reaction
catalyst
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005300310A
Other languages
English (en)
Inventor
Brigitte Leigh Ewanicki
Erik Jon Flahive
Annie Judith Kasparian
Mark Bryan Mitchell
Stacy Ann O'neill-Sla Wecki
Michael David Perry
Neal Willaim Sach
James Edward Saenz
Bing Shi
Jayaram Kasturi Srirangam
Nebojsa Slobodan Stankovic
Qingping Tian
Shu Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of AU2005300310A1 publication Critical patent/AU2005300310A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AU2005300310A 2004-11-02 2005-10-21 Methods of preparing indazole compounds Abandoned AU2005300310A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62463504P 2004-11-02 2004-11-02
US60/624,635 2004-11-02
US71707105P 2005-09-14 2005-09-14
US60/717,071 2005-09-14
PCT/IB2005/003297 WO2006048744A1 (en) 2004-11-02 2005-10-21 Methods of preparing indazole compounds

Publications (1)

Publication Number Publication Date
AU2005300310A1 true AU2005300310A1 (en) 2006-05-11

Family

ID=35744929

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005300310A Abandoned AU2005300310A1 (en) 2004-11-02 2005-10-21 Methods of preparing indazole compounds

Country Status (14)

Country Link
US (1) US7232910B2 (OSRAM)
EP (1) EP1809621A1 (OSRAM)
JP (1) JP2008518900A (OSRAM)
KR (1) KR20070058690A (OSRAM)
AR (1) AR051754A1 (OSRAM)
AU (1) AU2005300310A1 (OSRAM)
BR (1) BRPI0518203A2 (OSRAM)
CA (1) CA2586174A1 (OSRAM)
IL (1) IL182693A0 (OSRAM)
MX (1) MX2007005291A (OSRAM)
NO (1) NO20071619L (OSRAM)
RU (1) RU2007116107A (OSRAM)
TW (1) TWI294421B (OSRAM)
WO (1) WO2006048744A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101237588B1 (ko) 2007-04-05 2013-02-27 화이자 프로덕츠 인코포레이티드 포유동물에서의 비정상적인 세포 생장의 치료에 적합한 6-〔2-(메틸카바모일)페닐설파닐〕-3-e-〔2-(피리딘-2-일)에테닐〕인다졸의 결정질 다형체
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック, インコーポレイテッド チエノピリミジン化合物の製造方法
EP2163544A1 (en) * 2008-09-16 2010-03-17 Pfizer, Inc. Methods of preparing indazole compounds
CA2749012C (en) * 2009-01-08 2017-01-31 Merck Patent Gmbh Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof
KR20140069297A (ko) 2011-09-30 2014-06-09 화이자 인코포레이티드 N-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일-설파닐]-벤즈아미드의 약학 조성물
BR112014011453A2 (pt) 2011-11-11 2017-05-02 Pfizer n-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]-benzamida para o tratamento de leucemia mielógena crônica
US9899120B2 (en) 2012-11-02 2018-02-20 Nanotek Instruments, Inc. Graphene oxide-coated graphitic foil and processes for producing same
US10087073B2 (en) 2013-02-14 2018-10-02 Nanotek Instruments, Inc. Nano graphene platelet-reinforced composite heat sinks and process for producing same
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
ES2768678T3 (es) * 2013-12-06 2020-06-23 Vertex Pharma Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas
CN118286440A (zh) 2014-02-04 2024-07-05 辉瑞大药厂 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合
WO2015152117A1 (ja) * 2014-03-31 2015-10-08 千寿製薬株式会社 アルキニルインダゾール誘導体及びその用途
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
WO2016108106A1 (en) * 2014-12-29 2016-07-07 Shilpa Medicare Limited An improved process for preparation of axitinib
BR112017018234A2 (pt) 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
US9580406B2 (en) 2015-04-28 2017-02-28 Signa S.A. De C.V. Processes for the preparation of axitinib
KR102712880B1 (ko) 2015-06-16 2024-10-02 메르크 파텐트 게엠베하 Pd-l1 길항제 조합 치료
MX2019003755A (es) 2016-10-06 2019-08-12 Pfizer Regimen de dosificacion de avelumab para el tratamiento de cancer.
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
JP7200399B2 (ja) * 2019-04-18 2023-01-06 シントン・ビー.ブイ. アキシチニブの製造方法、中間体2-((3-ヨード-1h-インダゾール-6-イル)チオ)-n-メチルベンズアミドの精製方法、アキシチニブ塩酸塩によるアキシチニブの精製方法、アキシチニブ塩酸塩の固体形態
MX2024010773A (es) 2022-03-03 2024-09-10 Pfizer Anticuerpos multiespecificos y usos de estos.
WO2025157389A1 (en) 2024-01-22 2025-07-31 Iomx Therapeutics Ag Combinations of halogenated heterocyclic kinase inhibitors and vegfr inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
CA2517517C (en) * 2003-03-03 2012-12-18 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP2006522087A (ja) 2003-04-03 2006-09-28 ファイザー・インク Ag013736を含んでなる剤形
EP1885338A1 (en) 2005-05-19 2008-02-13 Pfizer, Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor

Also Published As

Publication number Publication date
IL182693A0 (en) 2007-09-20
TW200621721A (en) 2006-07-01
CA2586174A1 (en) 2006-05-11
RU2007116107A (ru) 2008-11-10
US20060094881A1 (en) 2006-05-04
JP2008518900A (ja) 2008-06-05
NO20071619L (no) 2007-04-25
US7232910B2 (en) 2007-06-19
KR20070058690A (ko) 2007-06-08
TWI294421B (en) 2008-03-11
AR051754A1 (es) 2007-02-07
BRPI0518203A2 (pt) 2009-03-10
EP1809621A1 (en) 2007-07-25
MX2007005291A (es) 2007-07-19
WO2006048744A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
AU2005300310A1 (en) Methods of preparing indazole compounds
US20070203196A1 (en) Methods of preparing indazole compounds
AU2022202494B2 (en) Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
AU2005300311A1 (en) Methods for preparing indazole compounds
TWI658042B (zh) 雜環化合物的合成
CA2349330C (en) Nitrogen containing heterobicycles as factor xa inhibitors
TWI603970B (zh) 雜環化合物之合成
CA2627839A1 (en) Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
CN102015720A (zh) 神经元烟碱性受体的选择性配体及其应用
TW201321378A (zh) 用於製造氮雜吲哚之方法及中間物
CA3157026A1 (en) Arylmethylene aromatic compounds as kv1.3 potassium shaker channel blockers
CN101094836A (zh) 制备吲唑化合物的方法
WO2016203112A1 (en) Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
EP3507282B1 (en) Process for preparing indole carboxamide compounds
RU2530775C2 (ru) ПРОИЗВОДНЫЕ 1Н-ПИРАЗОЛО[4,3-c]ИЗОХИНОЛИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ В ТЕРАПИИ
EP2163544A1 (en) Methods of preparing indazole compounds
WO2018109271A1 (en) New bromodomain inhibitors
CN114026095A (zh) 用于制备4-苯基-5-烷氧基羰基-2-噻唑-2-基-1,4-二氢嘧啶-6-基]甲基]-3-氧代-5,6,8,8a-四氢-1H-咪唑并[1,5-a]吡嗪-2-基]-甲酸的替代方法
US20050090668A1 (en) Preparation of 5-hydroxy-6-oxo-1,6-dihydropyrimidine compounds
HK40061337A (en) Alternative process for the preparation of [[[4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1h-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid
WO2025078335A1 (en) Processes for the preparation of deucravacitinib
JP2025526682A (ja) がんの治療のためのヘテロアリール化合物
TW202328074A (zh) 製備取代之吡唑并嘧啶之方法

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period